Xalkori (crizotinib capsules and oral pellets) — Cigna
Non-Small Cell Lung Cancer – ROS1 Rearrangement-Positive
Initial criteria
- Patient age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient has ROS1 rearrangement-positive disease
- Mutation detected by an approved test
Approval duration
1 year